Bristol-Myers Squibb Company

(New York Stock Exchange)
Back to all articles
Slightly Bearish -20

Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy ...

Drug pricing Patent expiry AI-generated analysis

πŸ“‰ Bristol Myers Squibb reported FY 2025 revenue of nearly $48.2 billion, a slight decrease of roughly 0.2% compared to the prior year.

πŸ’° The company achieved a net income recovery to close to $7.1 billion in FY 2025, resulting in a net margin of approximately 14.6%.

🏦 As of December 2025, BMY maintains a debt-to-equity ratio of roughly 2.6x and generated free cash flow of nearly $12.8 billion.

βš–οΈ The company faces intense pricing pressure from the Inflation Reduction Act impacting Medicare-set prices for key products like Eliquis and Pomalyst.

⚠️ Significant legal exposure exists due to a recently revived $6.7 billion lawsuit regarding contingent value rights linked to its Celgene acquisition.

πŸ”¬ Operational risks include the recent termination of an early-stage leukemia clinical trial within the oncology pipeline.

πŸ“ˆ BMY raised its full-year revenue outlook, and newer growth brands are currently gaining market traction.

πŸš€ Eliquis continues to defy expectations with stronger-than-anticipated growth despite regulatory pricing pressures.

πŸ“‰ The article notes that BMY faces significant revenue pressure from patent losses in the years ahead alongside drug pricing reforms.

πŸ† The Motley Fool analyst team did not identify Bristol Myers Squibb as one of their top 10 stocks for investors to buy now.

Bullish Signals
  • Net income recovered to close to $7.1 billion in FY 2025, marking a recovery from the net loss reported in the prior fiscal year.
  • The company generated strong free cash flow of nearly $12.8 billion as of its December 2025 balance sheet.
  • Bristol Myers Squibb raised its full-year revenue outlook, signaling improved near-term momentum for investors.
  • Newer growth brands are gaining traction, helping to offset the impact of patent expirations on legacy products.
  • Eliquis continues to defy expectations with stronger-than-anticipated growth despite regulatory pricing pressures.
Risk Factors
  • The company faces intense pricing pressure from the Inflation Reduction Act, which has led to Medicare-set prices for major products like Eliquis and Pomalyst.
  • Patent expirations for major products remain a primary concern, alongside ongoing generic and biosimilar competition eroding revenue.
  • The company deals with significant legal exposure, including a recently revived $6.7 billion lawsuit regarding contingent value rights linked to its Celgene acquisition.
  • There are inherent risks in the oncology pipeline highlighted by the recent termination of an early-stage leukemia clinical trial.
  • The article suggests BMY faces a longer stretch of uncertainty compared to competitors, with significant revenue pressure from patent losses in the years ahead.
Full Analysis
The article compares Bristol Myers Squibb (BMY) and Pfizer, concluding that Pfizer is the preferred investment despite both facing patent cliffs. It highlights BMY's recent recovery in net income to approximately $7.1 billion in FY 2025, a slight revenue decrease of 0.2% to $48.2 billion, and a debt-to-equity ratio of 2.6x. The company maintains strong free cash flow of nearly $12.8 billion. Bristol Myers Squibb is noted for its leadership in oncology and neuroscience, with strategic alliances including BioNTech and Johnson & Johnson. However, the stock faces significant headwinds from pricing pressure under the Inflation Reduction Act affecting products like Eliquis and Pomalyst, alongside patent expirations and generic competition. Specific risks identified for BMY include a revived $6.7 billion lawsuit regarding contingent value rights from its Celgene acquisition and the termination of an early-stage leukemia clinical trial. While the company raised its full-year revenue outlook and newer brands are gaining traction, the author argues that BMY faces a longer stretch of uncertainty compared to Pfizer's more visible post-patent roadmap. The analysis suggests that while BMY is slightly more affordable on a forward earnings basis, Pfizer offers a clearer path forward with growth in non-COVID products and an obesity drug portfolio. The Motley Fool analyst team did not include Bristol Myers Squibb in their top 10 stocks for immediate purchase, citing these structural challenges.